Clinical trials: Epilepsy Intractable
- Condition Epilepsy Intractable
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Dravet Syndrome
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
Stoke Therapeutics is evaluating the long-term safety \& tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen.
- Trial name
- NCT04740476
- Testing
- zorevunersen (STK-001)
- Where
- 17 sites in United States
- Volunteers
- 60 people
- Sponsor
- Stoke Therapeutics, Inc
Drug-Refractory Epilepsy
Rechargeable Implantable Vagus Nerve Stimulation System for Drug-Refractory Epilepsy
To evaluate the performance of automatic stimulation mode of a new rechargeable implantable vagus nerve stimulation system for drug-refractory epilepsy
- Trial name
- NCT05993117
- Testing
- G114R VNS system
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Pins Medical Co., Ltd
PCDH19-Related Epilepsy
Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)
A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in female children and young adults with genetically confirmed PCDH19 gene…
- Trial name
- NCT03865732
- Testing
- Ganaxolone
- Where
- 12 sites in United States, Hungary and 3 more
- Volunteers
- 29 people
- Sponsor
- Marinus Pharmaceuticals
Epilepsy
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
Vagus Nerve Stimulation (VNS) Therapy has been approved marked for the treatment of epilepsy since 1994. This post-market study is designed to follow the clinical course and outcomes for patients with refractory seizures treated…
- Trial name
- V-COMPAS (NCT01281293)
- Where
- 20 sites in United States, Belgium and 3 more
- Volunteers
- 124 people
- Sponsor
- Cyberonics, Inc.
Epilepsies, Partial
A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures
This study will evaluate the effectiveness and safety of seletracetam when it is used in addition to other anti-epileptic medications by patients with partial onset seizures. It will also help to determine the best dose to use.
- Trial name
- NCT00422110
- Testing
- Seletracetam
- Sponsor
- UCB Pharma
Refractory Epilepsy
Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy
This is a single site, non-randomized, prospective, open-label, interventional pilot/feasibility study. Patients recruited will have medically-refractory focal neocortical epilepsy, defined on the basis of presence of focal…
- Trial name
- NCT02866240
- Testing
- Cathodal Transcranial Direct Current Stimulation (tDCS).
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Neuroelectrics Corporation
Refractory Infantile Spasms
A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients.
- Trial name
- NCT03976076
- Testing
- JBPOS0101
- Where
- 23 sites in United States, South Korea
- Volunteers
- 16 people
- Sponsor
- Bio-Pharm Solutions Co., Ltd.
Infantile Spasms, Refractory Complex Partial Seizures in Adults
Sabril Patient Registry
The purpose of this study is to create a patient registry to collect and analyze information on subjects treated with Sabril and the prescribers of Sabril.
- Trial name
- NCT01073579
- Testing
- Sabril®
- Volunteers
- 9,423 people
- Sponsor
- Lundbeck LLC
Epilepsy
A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR
This is a safety and efficacy study of Keppra® extended release formulation - XR in patients with epilepsy.
- Trial name
- NCT00368069
- Testing
- Keppra® extended release formulation - XR
- Where
- 34 sites in Brazil, Finland and 5 more
- Volunteers
- 158 people
- Sponsor
- UCB Pharma
Epilepsy, Focal
A Study of Brivaracetam in Subjects With Partial Onset Seizures
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy
- Trial name
- NCT00175929
- Testing
- Brivaracetam
- Where
- 56 sites in Belgium, Czechia and 7 more
- Volunteers
- 157 people
- Sponsor
- UCB Pharma
Partial-onset Seizures
A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures
The purpose of this study is to confirm the efficacy and safety of perampanel compared to placebo in patients with refractory partial-onset seizures
- Trial name
- NCT01618695
- Testing
- Perampanel
- Where
- 117 sites in Australia, China and 5 more
- Volunteers
- 940 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy
Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.
This is a safety and efficacy study of add on therapy with seletracetam in patients experiencing refractory epilepsy.
- Trial name
- NCT00175864
- Testing
- Seletracetam (ucb 44212)
- Sponsor
- UCB Pharma
Seizures, Epilepsies, Partial
Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.
To evaluate the efficacy and safety of diazepam in the management of refractory epilepsy in selected patients who require intermittent medical intervention for the control of episodes of acute repetitive seizures.
- Conditions
- Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized
- Trial name
- NCT00319501
- Testing
- Vanquix Auto-Injector (Diazepam Injection)
- Where
- 86 sites in United States
- Volunteers
- 234 people
- Sponsor
- Pfizer
Epilepsy
Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
To assess the long-term effects of levetiracetam on retention rate in subjects with refractory partial onset seizure that are not fully controlled with 1 to 3 concomitant antiepileptic drugs, compared to topiramate as add-on…
- Trial name
- NCT01229735
- Testing
- Levetiracetam, Topiramate
- Where
- 24 sites in South Korea
- Volunteers
- 343 people
- Sponsor
- UCB Korea Co., Ltd.
Epilepsy
Non-interventional Study Describing Healthcare Resource Utilisation and Clinical Outcomes Associated With VNS Therapy in UK.
This is a UK, multi-center, non-interventional study based on the use of health service administrative and medical records (paper-based and/or electronic, as applicable) along with the use of prospectively collected…
- Trial name
- DANTE (NCT04779814)
- Where
- 5 sites in United Kingdom
- Volunteers
- 97 people
- Sponsor
- LivaNova
Tuberous Sclerosis Complex-associated Refractory Seizures
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures.
- Trial name
- EXIST-3 (NCT01713946)
- Testing
- RAD001, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
- Where
- 104 sites in United States, Argentina and 23 more
- Volunteers
- 366 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsies, Partial
Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients
Study to evaluate the pharmacokinetics, safety, and tolerability of OXC XR as adjunctive therapy in pediatric subjects with refractory partial epilepsy.
- Trial name
- NCT00918047
- Testing
- SPN-804O
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Epilepsy
Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures
To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic…
- Trial name
- NCT00334958
- Testing
- Rufinamide
- Where
- 77 sites in United States
- Volunteers
- 356 people
- Sponsor
- Eisai Inc.
Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
The purpose of this study is to determine whether Eslicarbazepine acetate (BIA 2-093) is an effective adjunct therapy in the treatment of refractory partial seizures
- Trial name
- NCT00988429
- Testing
- 800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate
- Where
- 162 sites in United States, Argentina and 9 more
- Volunteers
- 653 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy, Seizures
Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.
Multicenter global post-market registry of subjects diagnosed with drug resistant epilepsy and treated with the VNS Therapy System.
- Conditions
- Epilepsy, Seizures, Drug Resistant Epilepsy
- Trial name
- CORE-VNS (NCT03529045)
- Testing
- Vagus Nerve Stimulation (VNS) Therapy
- Where
- 62 sites in United States, Australia and 14 more
- Volunteers
- 827 people
- Sponsor
- LivaNova